How is generative AI transforming clinical trials?
April 10, 2025 | AI, clinical trials
Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.
The pharmaceutical industry is on the cusp of a groundbreaking transformation with the integration of generative AI — especially in clinical trials. By addressing the complexities and challenges traditionally linked to developing trials, recruiting patients and supporting them throughout their care journey, AI-driven innovations are accelerating the process of bringing drugs to market.
We recently attended the excellent DPHARM conference (16–17 September 2024, Philadelphia, USA), where many of these developments were discussed as potential methods of improving clinical research — both for patients and for pharmaceutical companies.
And as you can see from a few of the interesting statistics that we collected across the 2-day event, this innovation couldn’t come at a better time:
- 80% of trials face delays due to recruitment issues
- 11% of sites fail to enrol a single patient
- 55% of trials are terminated due to low accrual rates, with an average completion delay of 12 months
- 50% of patients live at least 125 miles from a trial site (this statistic is even more stark when we also know that they are typically willing to travel an average of 20.4 miles to attend appointments)
So how can generative AI help to solve these issues?
Site selection
Generative AI can significantly enhance site selection for clinical trials. By analysing extensive datasets such as demographic, historical trial performance and logistical data, AI is able to identify the most suitable trial locations.
Increasing the likelihood of choosing a site that matches the needs of the study ensures that the selected sites have the necessary resources and patient availability, which can streamline the trial process and reduce delays.
Finding diverse patient populations
Recruiting a diverse patient population for clinical trials is a major challenge. Generative AI tackles this by analysing large-scale health records and demographic databases to identify underserved communities.This approach not only enhances trial diversity, but also improves study generalisability (that is, the degree to which a study’s findings can be applied to other situations or groups of people).
Patient outreach
Effective communication with potential trial participants is essential. AI-powered platforms facilitate personalised and automated outreach, using predictive analytics to identify individuals who are likely to benefit from participating in particular studies and trials. This targeted approach boosts enrolment rates and maintains a steady flow of suitable participants.
Ethical and privacy concerns
So, those are the positives – but we also need to take a balanced view. While generative AI holds tremendous promise for transforming clinical trials, it also raises important ethical and privacy concerns. For example, the extensive use of health records and demographic data can potentially infringe on patient privacy if not handled with the utmost care. Which is why it’s crucial for pharmaceutical companies and AI developers to implement stringent data protection and anonymisation protocols to safeguard patient information.
There is also a risk of bias in AI algorithms if they’re not properly trained on diverse datasets, meaning that trial outcomes could be skewed, thereby limiting their applicability across different populations.Maintaining transparency in AI processes and ensuring equitable access to trials are imperative when addressing these concerns effectively.
But will the use of generative AI in clinical trials become widespread?
The FDA has recently issued guidance emphasising the importance of diversity in clinical trials. This guidance aims to ensure that clinical trials reflect the demographic makeup of the population that will eventually use the drug. By encouraging the inclusion of underrepresented groups, the FDA hopes to improve trial results and address healthcare disparities.
Due to its ability to efficiently identify and recruit diverse patient populations, AI could quickly become a valuable tool and play a pivotal role in ensuring the new FDA guidelines are upheld. By integrating the FDA’s diversity recommendations into AI-driven recruitment strategies, pharmaceutical companies will be able to foster more representative and equitable clinical research and align with regulatory expectations at the same time.
What does the future hold?
Isn’t that the question we all want answered?! One thing’s for sure though, it’s certainly an exciting time for the clinical trial space. And with the advent of new technologies and approaches, we think it likely that change and progress will be rapid and exponential. We’ll certainly be keeping a close eye on things.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.
Where translation falls short in practice
Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.
Where it all began – why we developed The Experience Gap
Learn how The Experience Gap was developed to help sponsors, CROs and site teams improve clinical trial participation by identifying friction points, enhancing patient experience, and driving better recruitment and...
Cuttsy+Cuttsy launches a practical roadmap to enhance clinical trial participant experience
Cuttsy+Cuttsy has launched The Experience Gap, a practical roadmap designed to help clinical trial teams improve participant engagement, support and retention across the full study journey.
Cuttsy+Cuttsy welcomes three new experts to the team
Cuttsy+Cuttsy is happy to be welcoming three new people to the team this month.